Adaptimmune Therapeutics announced that the first patient has been treated with TECELRA® (afamitresgene autoleucel), marking a significant milestone for the company. This event signifies the first commercial treatment with an engineered cell therapy for a solid tumor cancer approved in the U.S. and the first new therapy option for synovial sarcoma in over a decade.
The patient received treatment at Moffitt Cancer Center, one of Adaptimmune's Authorized Treatment Centers (ATCs) and a recognized leader in sarcoma research and treatment. TECELRA received accelerated approval from the U.S. Food and Drug Administration (FDA) in August 2024 for adults with unresectable or metastatic MAGE-A4 positive synovial sarcoma who have received prior chemotherapy and meet specific HLA criteria.
Adrian Rawcliffe, Adaptimmune's Chief Executive Officer, stated the company is focused on reaching as many eligible synovial sarcoma patients as possible with this one-time infusion treatment. Several ATCs are now accepting referrals across the U.S., and Adaptimmune is confident that its full network of approximately 30 ATCs will be active by the end of 2025, covering an estimated 80% of patients treated in sarcoma centers of excellence.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.